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esponsibility of InstAbstract CD38 is a multifunctional enzyme/receptor expressed in a variety of mammalian tissues,
regulating a wide range of physiological functions. Beginning with the previously reported compound 1,
an inhibitor of human CD38 NADase, we synthesized a series of indole-based NH-substituted derivatives
with modiﬁcations on alkyl chains, changes in substituent groups on aromatic rings, and differences in
carbon chain lengths. Compounds 10, 13, 16 and 34 exhibited moderate inhibition of human CD38
NADase. Analysis of the structure-activity relationships showed that the phenylpropionyl moiety was very
important for the inhibitory activity. This study provides information for the rational design of CD38
inhibitors.
& 2013 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
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CD38 is a 45-kD transmembrane protein ﬁrstly identiﬁed by
monoclonal antibody typing of lymphocytes and thus is thought of
as a lymphocyte-speciﬁc antigen1. It has now been established that
it is not lymphocyte-speciﬁc, but is ubiquitously expressed in
virtually all mammalian tissues examined2.
As a multi-functional protein and a member of the ADP-
ribosylcyclase family, CD38 can synthesize cyclic adenosine
diphosphate ribose(cADPR) and ADPR from nicotinamide ade-
nine dinucleotide (NAD+), and nicotinic acid adenine dinucleotide
phosphate (NAADP) from NAD phosphate (NADP+)3–5. The
likely mechanism has been informed by X-ray crystallographic
analysis6.
The membrane-bound enzyme CD38 exists in two opposing
orientations, type II and type III7, both of which can catalyze the
synthesis of cADPR and NAADP. As Ca2+ messenger molecules,
cADPR and NAADP have been shown to regulate a wide range of
physiological functions8. Gene knockout studies have established
that CD38 plays a critical role in a wide range of physiological
functions from insulin secretion9, immune response to bacterial
infection10, to modulate neuronal oxytocin secretion to affect
behavior in mice11. It has been proved that CD38 is directly
involved in many diseases, such as diabetes12, AIDS13 and chronic
lymphocytic leukemia14. It is thus of great interest to develop
speciﬁc and generally applicable inhibitors of CD38.
A series of CD38 inhibitors based on a computer-aided virtual
screening approach and structural optimization were studied by our
group previously. Compound 1 is the most active non-covalent
inhibitor of human CD38 NADase reported to date15. Because the
indole ring of compound 1 has an important π–π stacking with
CD38 and the para-benzoate feature is required by the activity, we
chose compound 1 as a lead compound and synthesized a series of
indole-based NH-substituted derivatives. Molecular docking studies
suggested the importance of the propylbenzyl group of compound 1O
n1
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Figure 1 Design of indole-ba
Scheme 1 Synthesis of compounds 5–27. Reagents and conditions: (a)
3: HCl, 30% H2O2, reﬂux, 3 h; (b) Ethyl 4-hydroxybenzoate, EDCI, DMAP
THF or DMF, 0 1C-r.t., 48 h.on binding, and to gain a better understanding of this structure-
activity relationship (SAR), modiﬁcation was mainly focused on
varying the alkyl chain length, placing substituent groups on the
aromatic ring, and altering the ring constituents (Fig. 1).2. Results and discussion
2.1. Synthetic routes
Compounds 5–27 were synthesized by a strategy similar to that
reported previously15 (Scheme 1), in a four-step reaction including
carboxylation, esteriﬁcation, reduction and amidation.
1-(3-Propionic acid) pyridium derivatives (28–30) were synthe-
sized as described in Scheme 2.
Compounds 31–35 were obtained after the deprotection of the
benzoxycarbonyl (Cbz) protecting group or the reduction of nitro-
group by catalytic hydrogenation (Scheme 3).
In this paper, we investigated and optimized the synthetic routes
of hydrogenation and amidation reactions reported in the litera-
ture15. When THF was used as the solvent for the Pd/C catalytic
hydrogenation reaction, byproduct 36 was generated easily along
with the main product, compound 4 (Scheme 4). The generation ofN
H
O
H
N
O
O
CO2C2H5
1
sed NH-substituted derivatives.
1: Oxalylchloride, ether, 0 1C-r.t., 24 h. 2: KOH, H2O, 90 1C, 1 h.
, DMF, 0 1C-r.t., 8 h; (c) H2, Pd/C, DMF/MeOH, r.t., 12 h; (d) EDCI,
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Scheme 3 Synthesis of compounds 31–35. Reagents and conditions: (a) H2, 10% Pd/C, THF, r.t., 12 h.
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Scheme 4 The side reaction of catalytic hydrogenation. Reagents and conditions: (a) H2, 10% Pd/C, THF, r.t., 12 h.
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ring-opening addition reaction as previously reported16. In addi-
tion, the yield of the amide-forming reaction, as described in the
literature15, is low and the product is difﬁcult to purify. Here, we
found that the intermediate generated by the reaction of R-COOH
and HOBt was too stable to further react with indole-NH2, and
therefore HOBt was not added in the amidation reaction.
2.2. Enzyme assay results
The synthetic compounds 5–27 and 31–36 were tested for their
inhibitory properties against the NAD-glycohydrolase activity of
the recombinant CD38. The results are shown in Table 1.
2.3. Structure-activity relationship analysis
In order to study the inﬂuence of the phenylpropionyl moiety in
lead compound 1 on the inhibitory activity, we designed and
synthesized compounds with aliphatic chain structures (5, 6) and
different carbon chain lengths (7–9) to examine the importance of
the aromatic ring and carbon chain length, respectively. The results
show that the aromatic ring and a chain length of three carbons are
required. A subsequent study of the effects of various aromatic
rings (10–15) on activity showed that phenyl ring is better than
other heteroaromatic rings. The introduction of different substi-
tuent groups to the phenyl ring (16–24, 33–35), including electron-
withdrawing groups and electron-donating groups, led to a
decrease in inhibitory activity. The position of substituent groups
usually caused activity to decrease to different degrees. Generally,
a meta-substituent reduced the activity less than a para-substituent
when substituted by a pyridine ring or electron-donating groups,
while para-substituents reduced the activity less than meta-
substituents when they included electron-withdrawing groups.
Thedifference in activity between10 and11 canbe explained from
the molecular docking analysis (Fig. 2). When the N atom of a
pyridine ring locates in the meta-position (10, green), the pyridine
ring can form a π–π stacking interaction with Trp125 and hydrogen-
bond with Glu226, which is similar to the lead compound (1, blue).
But when the N atom of the pyridine ring locates in the para-position
(11, brown), not only the hydrogenbond cannot be formedbecause of
the long distance, but also the binding mode is changed due to the
electronic property of the N atom. In addition to the hydrogen bond,
hydrophobic interactions and π–π stacking are generally veryimportant to the bindingof inhibitors. Thegoodactivity of compound
1might be partly attributed to potent π–π stacking with both Trp125
and Trp176, while this π–π interaction for other compounds may be
weaker due to the different orientations.
Our group17 has reported the crystal structure of CD38 associated
with an inhibitor containing a nicotinamide moiety. In this study,
a pyridium moiety was introduced (compounds 25–27), but these
compounds showed almost no activity. The previous crystal structure
showed that the compound containing the nicotinamide moiety can
not bind to the catalytic area (aroundGlu226/Trp125) and thus shows
very weak inhibitory activity. This also provides a possible explana-
tion for the above SAR: lead compound 1 has the best activity as a
result of the phenylpropionylmoietywhich can embed in the catalytic
pocket (aroundGlu226/Trp125) perfectly.Changing the length of the
carbon chain (7–9) ormodiﬁcations on the phenyl ringmay affect the
binding of the side chain to the catalytic pocket and lead to the
decrease of activity.
In conclusion, a series of indole-based NH-substituted deriva-
tives were synthesized, including compounds with different alkyl
side-chains, ring structures, and carbon chain lengths. Among
these derivatives, compounds 10, 13, 16 and 34 exhibit moderate
inhibition to human CD38 NADase. SAR analysis revealed that
the phenylpropionyl moieties in these compounds are likely
important to the anti-NADase activity. These studies provide
information for the future design of inhibitors of CD38.3. Experimental
3.1. Chemistry
All solvents and reagents were obtained from commercial sources
and used without further puriﬁcation unless otherwise stated.
Column chromatography was carried out on silica gel G60
(300–400 mesh). Thin-layer chromatography was performed on
silica gel G60 F254 with short-wavelength UV light for visualiza-
tion. 1H NMR and 13C NMR were recorded on a Bruker Avance
III 400 and were acquired using Bruker Topspin 2.1 acquisition
software. High-resolution mass spectra (HRMS) were recorded on
a Bruker Apex IV FTMS. Elemental analyses were done on a
Vario EL III instrument and were 70.3 of theoretical value.
Melting points were determined on a MelTemp apparatus.
Table 1 Structures and NADase inhibitory activity of the synthesized compounds.
Compd. R IC50 (μM) Compd. R IC50 (μM)
1 4.7 19 653
5 483 20 119
6 482 21 129
7 284 22 889
8 517 23 137
9 681 24 300
10 52 25 41000
11 783 26 41000
12 152 27 41000
13 78 31 489
14 660 32 774
15 460 33 138
16 55 34 63
17 111 35 247
18 133 36 – 41000
D. Wu et al.2483.2. General procedure for the synthesis of compounds 5–27
Compounds 2 and 3 were synthesized as reported15. Starting from
5-nitro-1H-indole, compound 2 was obtained with 62.0% yield,
which was esteriﬁed with ethyl 4-hydroxybenzoate for 8 h in DMF
to form compound 3 with 65.3% yield.
Compound 3 (354 mg, 1.0 mmol) was dissolved in 60 mL of
DMF/MeOH (1:1), adding 142 mg of 10% Pd/C (containing about55% water) to start catalytic hydrogenation under 55 psi overnight.
The reaction mixture was ﬁltered on celite and the solvent was
distilled off under vacuum. Flash column chromatography on
silica gel (CH2Cl2/MeOH) gave compound 4 as a gray solid
(290 mg, 89.5%). Mp 165–166 1C; 1H NMR (400 MHz, DMSO-
d6) δ 1.34 (t, J¼7.1 Hz, 3H), 4.34 (q, J¼7.1 Hz, 2H), 4.87
(s, 2H), 6.61 (dd, J¼8.7, 1.7 Hz, 1H), 7.21 (d, J¼8.3 Hz, 2H),
7.41 (d, J¼8.6 Hz, 2H), 8.05 (d, J¼8.6 Hz, 2H), 8.12 (d,
Figure 2 Predicted binding modes of 1(blue)/10(green)/11(brown) with CD38. Superimposition of binding modes of compounds 1/10/11 docked
into the binding site of CD38. Compound 10 can form π–π stacking with Trp125 and hydrogen bond with Glu226. Its binding mode is similar to
that of lead compound 1. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Novel indole derivatives as inhibitor of CD38 249J¼3.1 Hz, 1H), 11.82 (s, 1H). Compound 4 (76 mg, 0.235 mmol)
and Boc-L-glutamine (75 mg, 0.306 mmol) were dissolved in
30 mL of anhydrous CH2Cl2/anhydrous THF (1:1), cooled in an
ice bath and then EDCI (58 mg, 0.306 mmol) was added. The
reaction was stirred for 48 h at room temperature. The crude
mixture was puriﬁed by ﬂash column chromatography (CH2Cl2/
MeOH) to get compound 5 (102 mg, 78.5%). The same procedure
was followed to produce the desired compounds 6–27.3.2.1. (S)-4-(Ethoxycarbonyl)phenyl-5-[5-amino-2-(tert-butoxycar-
bonylamino)-5-oxopentanamido]-1H-indole-3-carboxylate (5)
White solid; Yield: 78.5%; Mp 185–186 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.51–1.19 (m, 12H), 1.85 (d, J¼43.7 Hz, 2H), 2.15
(s, 2H), 4.06 (s, 1H), 4.34 (q, J¼6.6 Hz, 2H), 6.78 (s, 1H), 7.01
(d, J¼7.1 Hz, 1H), 7.29 (s, 1H), 7.62–7.39 (m, 4H), 8.06
(d, J¼7.8 Hz, 2H), 8.33 (d, J¼5.8 Hz, 2H), 9.96 (s, 1H), 12.17
(s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.6, 28.3, 28.7, 32.1,
55.3, 61.3, 78.5, 105.3, 111.3, 113.0, 116.7, 123.0, 126.3, 127.4,
131.2, 133.6, 134.3, 135.2, 155.1, 155.8, 162.5, 165.6, 171.0,
174.1; Anal. Calcd. for C28H32N4O8: C, 60.86; H, 5.84; N, 10.14.
Found: C, 60.86; H, 5.80; N, 10.17; MS (ESI-TOF+) m/z 553
[M+H]+.3.2.2. 4-(Ethoxycarbonyl)phenyl-5-propionamido-1H-indole-3-
carboxylate (6)
White solid; Yield: 70.0%; Mp 230–231 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.09 (t, J¼6.6 Hz, 3H), 1.35 (t, J¼6.0 Hz, 3H), 2.32
(q, J¼6.5 Hz, 2H), 4.34 (q, J¼6.0 Hz, 2H), 7.49 (m, 4H), 8.07
(d, J¼6.9 Hz, 2H), 8.30 (d, J¼7.1 Hz, 2H), 9.84 (s, 1H), 12.14
(s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 10.3, 14.6, 30.0, 61.3,
105.3, 111.1, 112.9, 116.7, 123.0, 126.3, 127.4, 131.2, 133.4,
134.7, 135.1, 155.1, 162.5, 165.6, 172.0; Anal. Calcd. for
C21H20N2O5: C, 66.31; H, 5.30; N, 7.36. Found: C, 66.07;
H, 5.30; N, 7.45; MS (ESI-TOF+) m/z 381 [M+H]+.3.2.3. 4-(Ethoxycarbonyl)phenyl-5-(2-phenylacetamido)-1H-
indole-3-carboxylate (7)
White solid; Yield: 88.6%; Mp 219–220 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.34 (t, J¼7.0 Hz, 3H), 3.64 (s, 2H), 4.33
(q, J¼6.9 Hz, 2H), 7.24 (d, J¼6.8 Hz, 1H), 7.41–7.27 (m, 4H),
7.45 (dd, J¼15.1, 8.6 Hz, 3H), 7.58 (d, J¼8.7 Hz, 1H), 8.06
(d, J¼8.3 Hz, 2H), 8.32 (d, J¼5.3 Hz, 2H), 10.19 (s, 1H), 12.17
(s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2, 43.4, 60.8, 104.9,
110.7, 112.5, 116.2, 122.5, 125.9, 126.5, 127.0, 128.3, 129.1, 130.7,
133.1, 134.1, 134.7, 136.3, 154.6, 162.0, 165.2, 168.7; Anal. Calcd.
for C26H22N2O5: C, 70.58; H, 5.01; N, 6.33. Found: C, 70.46; H,
5.09; N, 6.30; MS (ESI-TOF+) m/z 443 [M+H]+.
3.2.4. 4-(Ethoxycarbonyl)phenyl-5-[2-(4-methoxyphenyl)acetami-
do]-1H-indole-3-carboxylate (8)
White solid; Yield: 83.0%; Mp 206–208 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.34 (t, J¼7.0 Hz, 3H), 3.55 (s, 2H), 3.72 (s, 3H),
4.34 (q, J¼7.0 Hz, 2H), 6.88 (d, J¼8.1 Hz, 2H), 7.26 (d, J¼8.0
Hz, 2H), 7.44 (m, 3H), 7.55 (d, J¼8.7 Hz, 1H), 8.06 (d, J¼8.4 Hz,
2H), 8.28 (s, 1H), 8.31 (s, 1H), 10.10 (s, 1H), 12.14 (s, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 14.6, 43.0, 55.5, 61.3, 105.3, 111.2,
112.9, 114.2, 116.6, 122.9, 126.3, 127.4, 128.7, 130.5, 131.2, 133.6,
134.6, 135.1, 155.1, 158.5, 162.4, 165.6, 169.5; Anal. Calcd. for
C27H24N2O6: C, 68.63; H, 5.12; N, 5.93. Found: C, 68.53; H, 5.13;
N, 5.76; MS (ESI-TOF+) m/z 473 [M+H]+.
3.2.5. 4-(Ethoxycarbonyl)phenyl-5-(4-phenylbutanamido)-1H-
indole-3-carboxylate (9)
White solid; Yield: 88.2%; Mp 191 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (s, 3H), 1.91 (s, 2H), 2.33 (s, 2H), 2.63 (s, 2H),
4.34 (d, J¼4.1 Hz, 2H), 7.39–7.14 (m, 5H), 7.45 (s, 3H), 7.55
(d, J¼7.6 Hz, 1H), 8.06 (d, J¼8.0 Hz, 2H), 8.31 (s, 2H), 9.88 (s,
1H), 12.14 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.6, 27.4,
35.2, 36.3, 61.3, 105.3, 111.2, 112.9, 116.7, 122.9, 126.2, 126.4,
127.4, 128.8, 128.8, 131.2, 133.5, 134.6, 135.1, 142.2, 155.1,
162.5, 165.6, 171.0; Anal. Calcd. for C28H26N2O5: C, 71.47; H,
D. Wu et al.2505.57; N, 5.95. Found: C, 71.33; H, 5.56; N, 6.02; MS (ESI-TOF+)
m/z 471 [M+H]+.3.2.6. 4-(Ethoxycarbonyl)phenyl-5-[3-(pyridin-3-yl)propanamido]-
1H-indole-3-carboxylate (10)
White solid; Yield: 80.4%; Mp 199–201 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼6.9 Hz, 3H), 2.66 (t, J¼7.1 Hz, 2H), 2.94
(t, J¼7.0 Hz, 2H), 4.34 (q, J¼6.9 Hz, 2H), 7.30 (s, 1H), 7.58–
7.39 (m, 4H), 7.67 (d, J¼7.4 Hz, 1H), 8.07 (d, J¼8.3 Hz, 2H),
8.27 (s, 1H), 8.32 (s, 1H), 8.39 (s, 1H), 8.49 (s, 1H), 9.92 (s, 1H),
12.15 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.6, 28.5, 37.9,
61.3, 105.3, 111.2, 112.9, 116.7, 123.0, 123.8, 126.3, 127.4,
131.2, 133.5, 134.4, 135.1, 136.3, 137.1, 147.7, 150.1, 155.1,
162.4, 165.6, 170.1; Anal. Calcd. for C26H23N3O5: C, 68.26; H,
5.07; N, 9.19. Found: C, 68.05; H, 5.04; N, 9.18; MS (ESI-TOF+)
m/z 458 [M+H]+.3.2.7. 4-(Ethoxycarbonyl)phenyl-5-[3-(pyridin-4-yl)propanamido]-
1H-indole-3-carboxylate (11)
White solid;Yield: 83.2%;Mp226 1C; 1HNMR(400 MHz,DMSO-
d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.68 (t, J¼7.6 Hz, 2H), 2.94 (t,
J¼7.5 Hz, 2H), 4.34 (q, J¼7.1 Hz, 2H), 7.28 (d, J¼5.7 Hz, 2H),
7.66–7.37 (m, 4H), 8.07 (d, J¼8.6 Hz, 2H), 8.28 (d, J¼1.3 Hz, 1H),
8.33 (d, J¼2.9 Hz, 1H), 8.45 (d, J¼5.8 Hz, 2H), 9.96 (s, 1H), 12.16
(s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2, 30.0, 36.4, 60.8,
104.8, 110.7, 112.5, 116.1, 122.5, 123.8, 125.9, 126.9, 130.7, 133.0,
133.9, 134.7, 149.4, 150.2, 154.6, 162.0, 165.1, 169.5; Anal. Calcd.
for C26H23N3O5: C, 68.26; H, 5.07; N, 9.19. Found: C, 68.23; H,
5.15; N, 9.15; MS (ESI-TOF+) m/z 458 [M+H]+.3.2.8. 4-(Ethoxycarbonyl)phenyl-5-[3-(furan-2-yl)propanamido]-
1H-indole-3-carboxylate (12)
White solid; Yield: 74.4%; Mp 195–196 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.0 Hz, 3H), 2.65 (t, J¼7.1 Hz, 2H), 2.94 (t,
J¼7.1 Hz, 2H), 4.34 (q, J¼7.0 Hz, 2H), 6.12 (s, 1H), 6.34
(s, 1H), 7.45 (t, J¼8.0 Hz, 3H), 7.60–7.49 (m, 2H), 8.07
(d, J¼8.5 Hz, 2H), 8.31 (d, J¼10.8 Hz, 2H), 9.98 (s, 1H), 12.15
(s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.6, 23.9, 35.0, 61.3,
105.3, 105.6, 110.8, 111.2, 112.9, 116.6, 123.0, 126.3, 127.4, 131.2,
133.5, 134.5, 135.1, 141.8, 155.1, 155.2, 162.5, 165.6, 170.0; Anal.
Calcd. for C25H22N2O6: C, 67.26; H, 4.97; N, 6.27. Found: C, 67.17;
H, 4.99; N, 6.28; MS (ESI-TOF+) m/z 447 [M+H]+.3.2.9. 4-(Ethoxycarbonyl)phenyl-5-[5-oxo-5-(thiophen-2-yl)pentan-
amido]-1H-indole-3-carboxylate (13)
Pale yellow solid; Yield: 71.2%; Mp 215 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.08–1.87 (m, 2H), 2.41
(t, J¼7.3 Hz, 2H), 3.03 (t, J¼7.2 Hz, 2H), 4.34 (q, J¼7.1 Hz,
2H), 7.23 (dd, J¼4.8, 3.9 Hz, 1H), 7.45 (dd, J¼8.6, 6.5 Hz, 3H),
7.55 (dd, J¼8.8, 1.8 Hz, 1H), 7.97 (dd, J¼11.9, 4.3 Hz, 2H), 8.06
(d, J¼8.7 Hz, 2H), 8.46–8.24 (m, 2H), 9.91 (s, 1H), 12.14 (s, 1H);
13C NMR (101 MHz, DMSO-d6) δ 14.6, 20.7, 25.6, 35.8, 38.2,
61.3, 67.5, 105.3, 111.2, 112.9, 116.7, 123.0, 126.3, 127.4, 129.2,
131.2, 133.5, 133.6, 134.6, 135.1, 144.3, 155.1, 162.5, 165.6,
170.8, 193.4; Anal. Calcd. for C27H24N2O6S: C, 64.27; H, 4.79;
N, 5.55. Found: C, 64.43; H, 4.90; N, 5.61; MS (ESI-TOF+) m/z
505 [M+H]+.3.2.10. (S)-4-(Ethoxycarbonyl)phenyl-5-[2-(tert-butoxycarbonyla-
mino)-3-(1H-imidazol-4-yl)-propanamido]-1H-indole-3-carboxylate
(14)
White solid; Yield: 70.0%; Mp 139–140 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.48–1.20 (m, 12H), 3.05–2.70 (m, 2H), 4.34
(q, J¼6.8 Hz, 3H), 6.81 (s, 1H), 6.99 (d, J¼6.5 Hz, 1H), 7.81–
7.30 (m, 5 H), 8.07 (d, J¼8.2 Hz, 2H), 8.31 (d, J¼11.3 Hz, 2H),
9.97 (s, 1H), 11.77 (s, 1H), 12.16 (s, 1H); 13C NMR (101 MHz,
DMSO-d6) δ 14.6, 28.5, 28.7, 55.6, 61.3, 78.6, 105.3, 111.4,
112.9, 116.8, 123.0, 126.3, 127.4, 131.2, 133.6, 134.3, 135.1,
155.1, 155.7, 162.4, 165.6, 170.7; HR-MS (ESI-TOF+) m/z Calcd.
for C29H32N5O7 [M+H]
+: 562.2296; found 562.2285.
3.2.11. (S)-4-(Ethoxycarbonyl)phenyl-5-[2-(tert-butoxycarbonyla-
mino)-3-(1H-indol-3-yl)-propanamido]-1H-indole-3-carboxylate(15)
White solid; Yield: 73.4%; Mp 152–153 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.45–1.19 (m, 12H), 3.02 (dd, J¼14.5, 8.9 Hz, 1H),
3.15 (dd, J¼14.4, 5.0 Hz, 1H), 4.53–4.21 (m, 3H), 6.90
(d, J¼8.0 Hz, 1H), 6.97 (t, J¼7.4 Hz, 1H), 7.05 (t, J¼7.4 Hz,
1H), 7.18 (s, 1H), 7.32 (d, J¼8.0 Hz, 1H), 7.46 (dd, J¼12.3,
8.9 Hz, 3H), 7.57 (d, J¼8.8 Hz, 1H), 7.67 (d, J¼7.8 Hz, 1H),
8.07 (d, J¼8.6 Hz, 2H), 8.44–8.23 (m, 2H), 10.05 (s, 1H), 10.81
(s, 1H), 12.17 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2,
27.9, 28.1, 55.7, 60.8, 78.0, 104.8, 110.0, 111.0, 111.2, 112.4,
116.4, 118.1, 118.6, 120.8, 122.5, 123.7, 125.8, 126.9, 127.3,
130.7, 133.1, 133.8, 134.7, 136.0, 154.6, 155.2, 162.0, 165.1,
170.7; Anal. Calcd. for C34H34N4O7: C, 66.87; H, 5.61; N, 9.17.
Found: C, 66.82; H, 5.72; N, 8.92; MS (ESI-TOF+) m/z 611
[M+H]+.
3.2.12. 4-(Ethoxycarbonyl)phenyl-5-[3-(4-chlorophenyl)propanam-
ido]-1H-indole-3-carboxylate (16)
White solid; Yield: 81.0%; Mp 199–201 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.0 Hz, 3H), 2.62 (t, J¼7.2 Hz, 2H), 2.91
(t, J¼7.1 Hz, 2H), 4.34 (q, J¼6.8 Hz, 2H), 7.31 (m, 4H), 7.44
(m, 3H), 7.53 (d, J¼8.8 Hz, 1H), 8.07 (d, J¼8.2 Hz, 2H), 8.27
(s, 1H), 8.33 (s, 1H), 9.92 (s, 1H), 12.16 (s, 1H); 13C NMR
(101 MHz, DMSO-d6) δ 14.2, 30.2, 37.7, 60.8, 104.8, 110.6,
112.4, 116.1, 122.5, 125.8, 126.9, 128.2, 130.2, 130.5, 130.7,
133.0, 134.0, 134.6, 140.3, 154.6, 162.0, 165.1, 169.7; Anal.
Calcd. for C27H23ClN2O5: C, 66.06; H, 4.72; N, 5.71. Found: C,
65.93; H, 4.74; N, 5.77; MS (ESI-TOF+) m/z 491 [M+H]+.
3.2.13. 4-(Ethoxycarbonyl)phenyl-5-[3-(3-chlorophenyl)propana-
mido]-1H-indole-3-carboxylate (17)
White solid; Yield: 87.8%; Mp 176–178 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.64 (t, J¼7.6 Hz, 2H), 2.93
(t, J¼7.6 Hz, 2H), 4.34 (q, J¼7.1 Hz, 2H), 7.27–7.18 (m, 2H),
7.39–7.27 (m, 2H), 7.49–7.39 (m, 3H), 7.52 (dd, J¼8.8, 1.8 Hz,
1H), 8.07 (d, J¼8.6 Hz, 2H), 8.27 (d, J¼1.4 Hz, 1H), 8.32 (d,
J¼2.9 Hz, 1H), 9.90 (s, 1H), 12.14 (d, J¼2.1 Hz, 1H); 13C NMR
(101 MHz, DMSO-d6) δ 14.2, 30.5, 37.5, 60.8, 104.8, 110.7,
112.5, 116.2, 122.5, 125.9, 125.9, 126.9, 127.0, 128.2, 130.1,
130.7, 132.9, 133.0, 134.0, 134.6, 143.9, 154.6, 162.0, 165.1,
169.7; Anal. Calcd. for C27H23ClN2O5: C, 66.06; H, 4.72; N, 5.71.
Found: C, 66.10; H, 4.83; N, 5.72; MS (ESI-TOF+) m/z 513
[M+Na]+.
3.2.14. 4-(Ethoxycarbonyl)phenyl-5-[3-(4-ﬂuorophenyl)propana-
mido]-1H-indole-3-carboxylate (18)
White solid; Yield: 86.5%; Mp 194–196 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.62 (t, J¼7.6 Hz, 2H), 2.91
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2H), 7.29 (dd, J¼8.4, 5.7 Hz, 2H), 7.45 (dd, J¼8.5, 6.2 Hz, 3H),
7.53 (dd, J¼8.8, 1.9 Hz, 1H), 8.07 (d, J¼8.7 Hz, 2H), 8.27
(d, J¼1.5 Hz, 1H), 8.32 (d, J¼3.1 Hz, 1H), 9.90 (s, 1H), 12.15
(d, J¼2.6 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.6, 30.6,
38.5, 61.3, 105.3, 111.2, 112.9, 115.3, 115.5, 116.7, 123.0, 126.3,
127.4, 130.5, 130.5, 131.2, 133.5, 134.5, 135.1, 137.9, 155.1,
160.0, 162.3, 162.5, 165.6, 170.3; Anal. Calcd. for C27H23FN2O5:
C, 68.35; H, 4.89; N, 5.90. Found: C, 68.36; H, 4.89; N, 5.95; MS
(ESI-TOF+) m/z 475 [M+H]+.
3.2.15. 4-(Ethoxycarbonyl)phenyl-5-[3-(2-ﬂuorophenyl)propana-
mido]-1H-indole-3-carboxylate (19)
White solid; Yield: 88.3%; Mp 187–188 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.64 (t, J¼7.7 Hz, 2H), 2.95
(t, J¼7.6 Hz, 2H), 4.35 (q, J¼7.1 Hz, 2H), 7.20–7.07 (m, 2H),
7.30–7.20 (m, 1H), 7.34 (t, J¼7.7 Hz, 1H), 7.45 (dd, J¼8.3,
5.8 Hz, 3H), 7.53 (dd, J¼8.8, 1.7 Hz, 1H), 8.07 (d, J¼8.6 Hz,
2H), 8.28 (d, J¼1.1 Hz, 1H), 8.33 (d, J¼2.8 Hz, 1H), 9.95
(s, 1H), 12.16 (s, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2,
24.2, 36.3, 60.8, 104.8, 110.7, 112.4, 115.0, 115.2, 116.2, 122.5,
124.3, 124.3, 125.8, 126.9, 127.7, 127.8, 128.0, 128.1, 130.7,
130.7, 133.0, 134.0, 134.6, 154.6, 159.3, 161.7, 162.0, 165.1,
169.6; Anal. Calcd. for C27H23FN2O5: C, 68.35; H, 4.89; N, 5.90.
Found: C, 68.15; H, 4.94; N, 5.91; MS (ESI-TOF+) m/z 475
[M+H]+.
3.2.16. 4-(Ethoxycarbonyl)phenyl-5-{3-[3-(triﬂuoromethyl)phenyl]
propanamido}-1H-indole-3-carboxylate (20)
White solid; Yield: 87.0%; Mp 203–205 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.68 (t, J¼7.6 Hz, 2H), 3.03
(t, J¼7.6 Hz, 2H), 4.34 (q, J¼7.1 Hz, 2H), 7.49–7.40 (m, 3H),
7.61–7.49 (m, 4H), 7.64 (s, 1H), 8.07 (d, J¼8.6 Hz, 2H), 8.27
(d, J¼1.4 Hz, 1H), 8.33 (s, 1H), 9.93 (s, 1H), 12.16 (s, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 14.6, 31.0, 38.0, 61.3, 105.3,
111.2, 113.0, 116.6, 120.7, 123.0, 123.1, 123.2, 123.2, 123.4,
125.2, 125.3, 125.3, 125.4, 126.1, 126.3, 127.4, 129.0, 129.2,
129.4, 129.7, 129.7, 130.0, 131.2, 133.0, 133.5, 134.4, 135.1,
143.3, 155.1, 162.5, 165.6, 170.2; Anal. Calcd. for
C28H23F3N2O5: C, 64.12; H, 4.42; N, 5.34. Found: C, 64.12; H,
4.35; N, 5.41; MS (ESI-TOF+) m/z 547 [M+Na]+.
3.2.17. 4-(Ethoxycarbonyl)phenyl-5-[3-(4-nitrophenyl)propanam-
ido]-1H-indole-3-carboxylate (21)
White solid; Yield: 83.3%; Mp 245–246 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼6.4 Hz, 3H), 2.70 (brs, 2H), 3.07 (brs,
2H), 4.35 (q, J¼6.4 Hz, 2H), 7.44 (m, 3H), 7.62–7.49 (m, 3H),
8.07 (d, J¼7.2 Hz, 2H), 8.16 (d, J¼7.3 Hz, 2H), 8.27 (s, 1H),
8.32 (s, 1H), 9.94 (s, 1H), 12.14 (s, 1H); 13C NMR (101 MHz,
DMSO-d6) δ 14.6, 31.1, 37.5, 61.3, 105.3, 111.2, 113.0, 116.7,
122.9, 123.9, 126.4, 127.4, 130.1, 131.2, 133.5, 134.4, 135.1,
146.4, 150.3, 155.1, 162.4, 165.6, 169.9; Anal. Calcd. for
C27H23N3O7: C, 64.67; H, 4.62; N, 8.38. Found: C, 64.55;
H, 4.73; N, 8.28; MS (ESI-TOF+) m/z 502 [M+H]+.
3.2.18. 4-(Ethoxycarbonyl)phenyl-5-[3-(3-nitrophenyl)propanam-
ido]-1H-indole-3-carboxylate (22)
White solid; Yield: 88.9%; Mp 203–204 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.71 (t, J¼7.5 Hz, 2H), 3.08
(t, J¼7.5 Hz, 2H), 4.35 (q, J¼7.1 Hz, 2H), 7.45 (dd, J¼8.5,
6.4 Hz, 3H), 7.52 (dd, J¼8.8, 1.8 Hz, 1H), 7.59 (t, J¼7.9 Hz,1H), 7.75 (d, J¼7.7 Hz, 1H), 8.07 (dd, J¼6.8, 1.9 Hz, 3H), 8.16
(s, 1H), 8.26 (d, J¼1.4 Hz, 1H), 8.33 (d, J¼3.0 Hz, 1H), 9.96
(s, 1H), 12.16 (d, J¼2.5 Hz, 1H); 13C NMR (101 MHz, DMSO-
d6) δ 14.2, 30.3, 37.3, 60.8, 104.8, 110.7, 112.5, 116.1, 121.0,
122.5, 122.9, 125.8, 126.9, 129.7, 130.7, 133.0, 133.9, 134.7,
135.4, 143.7, 147.8, 154.6, 162.0, 165.1, 169.5; Anal. Calcd. for
C27H23N3O7: C, 64.67; H, 4.62; N, 8.38. Found: C, 64.61;
H, 4.76; N, 8.41; MS (ESI-TOF+) m/z 524 [M+Na]+.
3.2.19. 4-(Ethoxycarbonyl)phenyl-5-[3-(4-methoxyphenyl)propan-
amido]-1H-indole-3-carboxylate (23)
White solid; Yield: 75.4%; Mp 201–202 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.58 (t, J¼7.6 Hz, 2H), 2.86
(t, J¼7.6 Hz, 2H), 3.70 (s, 3H), 4.34 (q, J¼7.1 Hz, 2H), 6.83
(d, J¼8.5 Hz, 2H), 7.16 (d, J¼8.5 Hz, 2H), 7.44 (dd, J¼8.3,
6.0 Hz, 3H), 7.53 (dd, J¼8.8, 1.7 Hz, 1H), 8.06 (d, J¼8.6 Hz,
2H), 8.28 (s, 1H), 8.31 (d, J¼3.0 Hz, 1H), 9.87 (s, 1H), 12.13
(d, J¼2.3 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2, 30.1,
38.3, 54.9, 60.8, 104.8, 110.7, 112.4, 113.7, 116.2, 122.5, 125.9,
126.9, 129.2, 130.7, 133.0, 133.1, 134.1, 134.6, 154.6, 157.5,
162.0, 165.1, 170.0; Anal. Calcd. for C28H26N2O6: C, 69.12; H,
5.39; N, 5.76. Found: C, 69.11; H, 5.41; N, 5.79; MS (ESI-TOF+)
m/z 509 [M+Na]+.
3.2.20. 4-(Ethoxycarbonyl)phenyl-5-[3-(3,4,5-trimethoxyphenyl)
propanamido]-1H-indole-3-carboxylate (24)
White solid; Yield: 82.8%; Mp 173–174 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.62 (t, J¼7.7 Hz, 2H), 2.87
(t, J¼7.6 Hz, 2H), 3.60 (s, 3H), 3.73 (s, 6 H), 4.34 (q, J¼7.1 Hz,
2H), 6.56 (s, 2H), 7.50–7.38 (m, 3H), 7.54 (dd, J¼8.8, 2.0 Hz,
1H), 8.13–8.01 (m, 2H), 8.29 (d, J¼1.7 Hz, 1H), 8.33
(d, J¼2.5 Hz, 1H), 9.93 (s, 1H), 12.16 (s, 1H); 13C NMR
(101 MHz, DMSO-d6) δ 14.2, 31.4, 38.0, 55.7, 59.9, 60.8,
104.8, 105.4, 110.7, 112.5, 116.2, 122.5, 125.8, 126.9, 130.7,
133.0, 134.0, 134.6, 135.6, 136.9, 152.7, 154.6, 162.0, 165.1,
170.1; Anal. Calcd. for C30H30N2O8: C, 65.92; H, 5.53; N, 5.13.
Found: C, 65.94; H, 5.68; N, 5.07; MS (ESI-TOF+) m/z 547
[M+H]+.
3.2.21. 1-(3-(3-{[4-(Ethoxycarbonyl)phenoxy]carbonyl}-1H-indol-
5-ylamino)-3-oxopropyl)pyridinium chloride (25)
Compound 4 was reacted with compound 28 to afford the desired
compound 25 following the same procedure of compound 5.
White solid; Yield: 80.0%; Mp 194–195 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 3.20 (t, J¼6.5 Hz, 2H), 4.35
(q, J¼7.1 Hz, 2H), 4.94 (t, J¼6.4 Hz, 2H), 7.60–7.34 (m, 4H),
8.12–7.98 (m, 2H), 8.24–8.11 (m, 2H), 8.46–8.25 (m, 2H), 8.59
(t, J¼7.8 Hz, 1H), 9.19 (d, J¼5.6 Hz, 2H), 10.38 (s, 1H), 12.29
(d, J¼2.6 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2, 36.6,
57.1, 60.8, 104.8, 110.8, 112.6, 116.1, 122.4, 125.9, 126.9, 127.7,
130.7, 133.2, 133.4, 134.7, 145.3, 145.7, 154.6, 161.9, 165.1,
167.2; HR-MS (ESI-TOF+) m/z Calcd. for C26H24ClN3O5
[M–Cl]+: 458.1710; found 458.1704.
3.2.22. 3-Carbamoyl-1-(3-(3-{[4-(ethoxycarbonyl)phenoxy]car-
bonyl}-1H-indol-5-ylamino)-3-oxopropyl)pyridinium chloride (26)
Compound 4 was reacted with compound 29 to afford the desired
compound 26 following the same procedure of compound 5.
White solid; Yield: 81.6%; Mp 231–232 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 3.26 (t, J¼6.2 Hz, 2H), 4.34
(q, J¼7.1 Hz, 2H), 4.99 (t, J¼6.1 Hz, 2H), 7.56–7.36 (m, 4H),
D. Wu et al.2528.06 (d, J¼8.6 Hz, 2H), 8.16 (s, 1H), 8.28–8.21 (m, 1H), 8.31
(d, J¼9.3 Hz, 2H), 8.79 (s, 1H), 8.98 (d, J¼8.1 Hz, 1H), 9.30
(d, J¼6.0 Hz, 1H), 9.70 (s, 1H), 10.38 (s, 1H), 12.30 (s, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 14.7, 36.8, 58.0, 61.3, 105.3,
111.3, 113.1, 116.6, 122.9, 126.4, 127.4, 127.9, 131.2, 133.7,
133.9, 134.0, 135.2, 144.2, 145.8, 147.6, 155.1, 162.4, 163.3,
165.6, 167.8; Anal. Calcd. for C27H25ClN4O6: C, 60.39; H, 4.69;
N, 10.43. Found: C, 60.28; H, 4.77; N, 10.26; MS (ESI-TOF+) m/z
501 [M-Cl]+.
3.2.23. 4-Carbamoyl-1-(3-(3-{[4-(ethoxycarbonyl)phenoxy]carb-
onyl}-1H-indol-5-ylamino)-3-oxopropyl)pyridinium chloride (27)
Compound 4 was reacted with compound 30 to afford the desired
compound 27 following the same procedure of compound 5.
White solid; Yield: 79.2%; Mp 201–203 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 3.23 (t, J¼6.3 Hz, 2H), 4.34
(q, J¼7.1 Hz, 2H), 4.97 (t, J¼6.3 Hz, 2H), 7.56–7.35 (m, 4H),
8.06 (d, J¼8.7 Hz, 2H), 8.26 (s, 1H), 8.32 (d, J¼2.7 Hz, 2H),
8.47 (d, J¼6.7 Hz, 2H), 8.80 (s, 1H), 9.35 (d, J¼6.6 Hz, 2H),
10.42 (s, 1H), 12.32 (d, J¼2.7 Hz, 1H); 13C NMR (101 MHz,
DMSO-d6) δ 14.7, 36.9, 57.6, 61.3, 105.3, 111.3, 113.1, 116.6,
122.9, 126.0, 126.4, 127.4, 131.2, 133.7, 134.0, 135.1, 146.8,
148.9, 155.1, 162.4, 163.9, 165.6, 167.7; HR-MS (ESI-TOF+) m/z
Calcd. for C27H25ClN4O6 [M-Cl]
+: 501.1769; found 501.1762.
3.3. General procedure for the synthesis of compounds 28–30
3-Chloropropionic acid (673 mg, 6.2 mmol) was added to 20 mL
anhydrous acetonitrile containing pyridine (0.5 mL, 6.2 mmol).
The reaction was reﬂuxed for 12 h and the solution was concen-
trated under reduced pressure. The crude product was recrystal-
lized from MeOH/H2O to obtain compound 28 (1.05 g, 90.5%).
The similar procedure was followed to produce the desired
compounds 29–30.
3.3.1. 1-(2-Carboxyethyl)pyridinium chloride (28)
White crystal; 1H NMR (400 MHz, DMSO-d6) δ 3.10 (t, J¼6.7
Hz, 2H), 4.83 (t, J¼6.6 Hz, 2H), 8.16 (t, J¼6.8 Hz, 2H), 8.62
(t, J¼7.7 Hz, 1H), 9.15 (d, J¼5.5 Hz, 2H), 12.66 (s, 1H).
3.3.2. 3-Carbamoyl-1-(2-carboxyethyl)pyridinium chloride (29)
White crystal; Yield: 86.3%; 1H NMR (400 MHz, DMSO-d6) δ
3.15 (t, J¼6.7 Hz, 2H), 4.87 (t, J¼6.7 Hz, 2H), 8.18 (s, 1H), 8.28
(dd, J¼8.0, 6.2 Hz, 1H), 8.61 (s, 1H), 8.97 (d, J¼8.2 Hz, 1H),
9.27 (d, J¼6.1 Hz, 1H), 9.57 (s, 1H), 12.72 (s, 1H).
3.3.3. 4-Carbamoyl-1-(2-carboxyethyl)pyridinium chloride (30)
White crystal; Yield: 89.1%; 1H NMR (400 MHz, DMSO-d6) δ
3.14 (t, J¼6.6 Hz, 2H), 4.87 (t, J¼6.6 Hz, 2H), 8.28 (s, 1H), 8.54
(d, J¼6.4 Hz, 2H), 9.00 (s, 1H), 9.34 (d, J¼6.1 Hz, 2H), 12.82
(s, 1H).
3.4. General procedure for the synthesis of compounds 31–35
Compounds 31–35 needed further catalytic hydrogenation after
completion of the amidation reaction. The reactants Cbz-31, Cbz-
32, 21, 22 were prepared using the same procedure producing
compound 5, and then reduced to corresponding products 31–33,
Using the procedure for producing compound 4 but changing the
solvent to THF. Compounds 34 and 35 were generated as same as
described in Scheme 4.3.4.1. (S)-4-(Ethoxycarbonyl)phenyl-5-(2-amino-3-phenylpropan-
amido)-1H-indole-3-carboxylate (31)
White solid; Yield: 63.6%; Mp 207–208 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 1.87 (s, 2H), 2.73 (dd,
J¼13.3, 7.9 Hz, 1H), 3.01 (dd, J¼13.3, 5.5 Hz, 1H), 3.58 (dd,
J¼7.7, 5.7 Hz, 1H), 4.35 (q, J¼7.1 Hz, 2H), 7.22–7.12 (m, 1H),
7.26 (m, 4H), 7.58–7.39 (m, 4H), 8.07 (d, J¼8.6 Hz, 2H), 8.30
(d, J¼1.1 Hz, 1H), 8.33 (s, 1H), 9.85 (s, 1H), 12.17 (s, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 14.7, 41.7, 57.6, 61.3, 105.3,
111.4, 113.0, 116.8, 123.0, 126.3, 126.5, 127.4, 128.5, 129.8,
131.2, 133.6, 134.1, 135.2, 139.2, 155.1, 162.5, 165.6, 173.6;
Anal. Calcd. for C27H25N3O5: C, 68.78; H, 5.34; N, 8.91. Found:
C, 68.67; H, 5.44; N, 8.83; MS (ESI-TOF+) m/z 472 [M+H]+.
3.4.2. (R)-4-(Ethoxycarbonyl)phenyl-5-(2-amino-3-phenylpropa-
namido)-1H-indole-3-carboxylate (32)
White solid; Yield: 61.8%; Mp 207 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼6.7 Hz, 3H), 1.89 (s, 2H), 2.72
(dd, J¼12.8, 8.2 Hz, 1H), 3.01 (dd, J¼13.2, 5.1 Hz, 1H),
3.74–3.47 (m, 1H), 4.34 (dd, J¼13.7, 6.7 Hz, 2H), 7.22 (m,
5 H),7.62–7.37 (m, 4H), 8.07 (d, J¼8.3 Hz, 2H), 8.30 (s, 1H),
8.33 (s, 1H), 9.85 (s, 1H), 12.17 (s, 1H); 13C NMR (101 MHz,
DMSO-d6) δ 14.7, 41.7, 57.5, 61.3, 105.3, 111.4, 113.0, 116.8,
123.0, 126.3, 126.5, 127.4, 128.5, 129.8, 131.2, 133.6, 134.1,
135.2, 139.2, 155.1, 162.5, 165.6, 173.6; Anal. Calcd. for
C27H25N3O5: C, 68.78; H, 5.34; N, 8.91. Found: C, 68.90; H,
5.35; N, 8.99; MS (ESI-TOF+) m/z 472 [M+H]+.
3.4.3. 4-(Ethoxycarbonyl)phenyl-5-[3-(4-aminophenyl)propanam-
ido]-1H-indole-3-carboxylate (33)
White solid; Yield: 91.5%; Mp 185–186 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (s, 3H), 2.51 (s, 2H), 2.74 (s, 2H), 4.35
(d, J¼6.5 Hz, 2H), 4.81 (s, 2H), 6.48 (d, J¼7.2 Hz, 2H), 6.90
(d, J¼6.1 Hz, 2H), 7.49 (m, 4H), 8.07 (d, J¼7.7 Hz, 2H), 8.30
(d, 2H), 9.85 (s, 1H), 12.13 (s, 1H); 13C NMR (101 MHz, DMSO-
d6) δ 14.6, 30.8, 39.2, 61.3, 105.3, 111.2, 112.9, 114.5, 116.7,
122.9, 126.3, 127.4, 128.7, 129.1, 131.2, 133.5, 134.6, 135.1,
147.0, 155.1, 162.5, 165.6, 170.8; Anal. Calcd. for C27H25N3O5:
C, 68.78; H, 5.34; N, 8.91. Found: C, 68.74; H, 5.42; N, 8.86; MS
(ESI-TOF+) m/z 472 [M+H]+.
3.4.4. 4-(Ethoxycarbonyl)phenyl-5-[3-(3-aminophenyl)propana-
mido]-1H-indole-3-carboxylate (34)
White solid; Yield: 35.5%; Mp 179–180 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 2.56 (t, J¼7.8 Hz, 2H),
2.84–2.69 (m, 2H), 4.35 (q, J¼7.1 Hz, 2H), 4.98 (s, 2H), 6.39
(dd, J¼12.0, 4.7 Hz, 2H), 6.45 (s, 1H), 6.91 (t, J¼7.7 Hz, 1H),
7.51–7.40 (m, 3H), 7.56 (dd, J¼8.8, 1.9 Hz, 1H), 8.13–8.03
(m, 2H), 8.32 (dd, J¼10.7, 2.4 Hz, 2H), 9.91 (s, 1H), 12.16
(d, J¼2.8 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 14.2, 31.2,
38.1, 60.8, 104.8, 110.6, 111.7, 112.4, 113.9, 115.7, 116.2, 122.5,
125.8, 126.9, 128.7, 130.7, 133.0, 134.1, 134.6, 141.8, 148.5,
154.6, 162.0, 165.1, 170.1; Anal. Calcd. for C27H25N3O5: C,
68.78; H, 5.34; N, 8.91. Found: C, 68.58; H, 5.51; N, 8.83; MS
(ESI-TOF+) m/z 494 [M+Na]+.
3.4.5. 4-(Ethoxycarbonyl)phenyl-5-{3-[3-(4-hydroxybutylamino)
phenyl]propanamido}-1H-indole-3-carboxylate (35)
White solid; Yield: 43.8%; Mp 130–131 1C; 1H NMR (400 MHz,
DMSO-d6) δ 1.35 (t, J¼7.1 Hz, 3H), 1.62–1.43 (m, 4H), 2.57
(t, J¼7.7 Hz, 2H), 2.79 (t, J¼7.7 Hz, 2H), 2.96 (t, J¼6.1 Hz,
Novel indole derivatives as inhibitor of CD38 2532H), 3.40 (s, 2H), 4.51–4.25 (m, 3H), 5.45 (s, 1H), 6.51–6.32 (m,
3H), 6.96 (t, J¼7.7 Hz, 1H), 7.45 (dd, J¼8.6, 4.9 Hz, 3H), 7.56
(dd, J¼8.8, 1.7 Hz, 1H), 8.07 (d, J¼8.6 Hz, 2H), 8.31 (dd,
J¼11.4, 2.1 Hz, 2H), 9.91 (s, 1H), 12.16 (d, J¼2.6 Hz, 1H); 13C
NMR (101 MHz, DMSO-d6) δ 14.2, 25.3, 30.2, 31.4, 38.1, 42.8,
60.5, 60.8, 104.8, 109.8, 110.6, 111.7, 112.4, 115.4, 116.2, 122.5,
125.8, 126.9, 128.7, 130.7, 133.0, 134.1, 134.6, 141.8, 149.1,
154.6, 162.0, 165.1, 170.2; Anal. Calcd. for C31H33N3O6: C,
68.49; H, 6.12; N, 7.73. Found: C, 68.69; H, 6.34; N, 7.53; MS
(ESI-TOF+) m/z 544 [M+H]+.
3.5. General procedure for the synthesis of compound 36
3.5.1. 4-(Ethoxycarbonyl)phenyl-5-(4-hydroxybutylamino)-1H-
indole-3-carboxylate (36)
Compound 3 (142 mg, 0.4 mmol) was dissolved in 40 mL of THF,
and added 57 mg of 10% Pd/C (containing about 55% water) to
start catalytic hydrogenation under 55 psi overnight. The reaction
mixture was ﬁltered on celite and the solvent was distilled off
under vacuum. Flash column chromatography on silica gel
(CH2Cl2/CH3OH) gave 71 mg compound 4 and 44 mg compound
36. Orange solid; Mp 159–160 1C; 1H NMR (400 MHz, DMSO-
d6) δ 1.35 (t, J¼7.0 Hz, 3H), 1.73–1.45 (m, 4H), 3.01 (dd,
J¼12.2, 6.3 Hz, 2H), 3.42 (dd, J¼11.6, 5.9 Hz, 2H), 4.34
(q, J¼7.1 Hz, 2H), 4.41 (t, J¼5.0 Hz, 1H), 5.36 (t, J¼5.3 Hz,
1H), 6.65 (d, J¼8.8 Hz, 1H), 7.10 (s, 1H), 7.25 (d, J¼8.7 Hz,
1H), 7.41 (d, J¼8.3 Hz, 2H), 8.05 (d, J¼8.3 Hz, 2H), 8.12
(d, J¼2.7 Hz, 1H), 11.82 (s, 1H); 13C NMR (101 MHz, DMSO-
d6) δ 14.7, 25.9, 30.8, 44.2, 61.1, 61.2, 100.5, 104.1, 112.5, 113.3,
122.9, 127.2, 127.8, 129.8, 131.1, 133.3, 145.6, 155.3, 162.6,
165.6; Anal. Calcd. for C22H24N2O5: C, 66.65; H, 6.10; N, 7.07.
Found: C, 66.45; H, 6.11; N, 7.03; MS (ESI-TOF+) m/z 397
[M+H]+.
3.6. Enzyme assay
Enzyme assays were conducted as reported previously15. Inhibi-
tion of the NADase reaction of CD38 by the compounds was
determined by mixing different concentrations of the compounds
with the recombinant CD38 and bovine serum albumin. NAD was
added to the mixture to start the reaction. Aliquots of the reaction
mixture were taken at t¼0, 4, 8 and 12 min by adding HCl,
followed by neutralization. The subsequent cycling reaction was
conducted in 96-well plates and the IC50 value was obtained by
measuring the rate of the increase in resoruﬁn ﬂuorescence with
comparison to the control without inhibitor.
3.7. Docking procedures
The molecular docking process was based on the literature15. The
newest crystal structure of CD38 (PDB code: 3ROK) was prepared
using the “Prepare Protein” Protocol of Discovery Studio2.5
(Accelrys, SanDiego, CA), andwas used as the receptor for docking.
The structures of eachchemicalweredrawn inChemDrawUltra11.0,
and used as the ligands for docking after being prepared by the
“Prepare Ligand” Protocol of Discovery Studio2.5 (Accelrys, San
Diego, CA). The docking process was carried out with GOLD 5.1
suite (Cambridge Crystallographic Data Center, Cambridge, UK).The binding sitewas deﬁned by the ligand in the crystal structure, and
the radius was set to 7 Å. CHEMPLP Score was used to evaluate and
rank the poses. Every GA run was set to 100 times.
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